Merck says experimental skin disease drug meets main goal in mid-stage study
30/09/2026 13:22
Merck says experimental skin disease drug meets main goal in mid-stage study Sept 30 (Reuters) - Merck MRK.N said on Wednesday its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps, abscesses and scarring.
(Reporting by Sahil Pandey in Bengaluru; Editing by Shreya Biswas)
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines